Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2002-09-01
To characterize the safety and efficacy of rFIX in children less than 6 years of age with
severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.
This study will provide an opportunity for systematic observation of treatment with rFIX in
children less than 6 years of age regardless of prior FIX treatment. Younger patients exhibit
a different pharmacokinetic profile and therefore may respond differently to rFIX infusions
when compared with older children and adults. This evaluation will provide data from which
recommendations can be made regarding rFIX dosing and treatment of these patients.
Surveillance for certain observations that have been made in patients treated with rFIX in
the clinical and postmarketing setting will be performed, including inhibitor development,
thrombogenicity, FIX recovery/lack of effect, allergic-type manifestations, and RBC
agglutination. Comparisons will be derived from published reports and communications
describing experience with other FIX products and protein therapeutics in general.
The primary objective of this clinical research study is to assess the safety and efficacy of
rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C
≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor
surgical procedures).
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
1969-12-31
The primary objective of this clinical research study is to establish the bioequivalence of 2
treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
